UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

 

 

For themonth of November 2025

 

CommissionFile Number 001-15170

 

 

GSK plc

(Translationof registrant's name into English)

 

 

79 New Oxford Street, London, WC1A 1DG

(Addressof principal executive office)

 

 

 

Indicateby check mark whether the registrant files or will file annualreports under cover of Form 20-F or Form 40-F.

 

Form20-F . . . .X. . . . Form 40-F . . . . . . . .

 

 

Issued: 19 November 2025, London UK

 

Transfer of Treasury Shares

 

 

On 18 November 2025, GSK plc (the "Company")transferred 22,000,000 ordinary shares of 31¼ penceeach ("Ordinary Shares") that were held by the Company in treasury("Treasury Shares") to the Company's Jersey resident trust, theGlaxoSmithKline Employee Trust (the "Jersey Trust"), such OrdinaryShares to be used to satisfy awards granted under the Company'sDeferred Annual Bonus Plan, Performance Share Plan and Share ValuePlan. The consideration received fromthe trustee of the Jersey Trust, of £17.995 per Ordinary Share, was funded bya loan from GlaxoSmithKline Services Unlimited.

 

Following the transfer, the Company will hold234,819,844 Ordinary Shares in treasury andhave 4,080,611,266 Ordinary Shares in issue(excluding Treasury Shares).

 

The total number of voting rights inthe Company is 4,080,611,266. This figure may be used byshareholders as the denominator for the calculations by which theywill determine if they are required to notify their interest in, ora change to their interest in, the Company under the FinancialConduct Authority's Disclosure Guidance and TransparencyRules.

 

The Company confirms that, in accordance with DTR 5.5.1R, followingthe above transfer the percentage of voting rights attributable tothe Treasury Shares is 5.75%.

 

This announcement is made in accordance with the requirements of UKListing Rule 9.8.2.

 

Notifications may be sent to company.secretary@gsk.com.

 

 

V A Whyte

Company Secretary

 

19 November 2025

 

 

About GSK

GSK is a global biopharma company with a purpose to unite science,technology, and talent to get ahead of disease together. Find outmore at www.gsk.com.

 

Registered in England & Wales: 

No.3888792

 

Registered Office:

79New Oxford Street

London

WC1A1DG

 

 

 

 

 

SIGNATURES

 

 

Pursuantto the requirements of the Securities Exchange Act of 1934, theregistrant has duly caused this report to be signed on its behalfby the undersigned, thereunto duly authorised.

	GSK plc
	(Registrant)
Date: November19, 2025
	By:/s/ VICTORIAWHYTE --------------------------
	Victoria Whyte
	AuthorisedSignatory for and on
	behalfof GSK plc